

DEPARTMENT OF COMMERCE, COMMUNITY, AND ECONOMIC DEVELOPMENT
DIVISION OF CORPORATIONS, BUSINESS AND PROFESSIONAL LICENSING

BOARD OF PHARMACY

CONDENSED MINUTES OF THE MEETING HELD FEBRUARY 15, 2024

Date: February 15, 2024
Time: 09:00am – 05:00pm
Location: Online via Zoom™

Attending: Board Members: Ashley Schaber, Sara Rasmussen, Carla Hebert, Ramsey Bell, James Henderson, and Sylvain Novion.
Staff: Michael Bowles, Lisa Sherrell, Billy Homestead, and Holly Handley.

Absent:

Agenda Item #1. Roll Call/Call to Order – Board and Staff Introductions

Roll Call:

Ashley Schaber - Present
Sara Rasmussen - Absent
James Henderson - Present
Carla Hebert - Present
Ramsey Bell – Present
Sylvain Novion – Present

On the record at 09:04am.

Sara Rasmussen joined the meeting at 9:08am.

Agenda Item #2 Ethics Disclosures

Brief Discussion: Ashley Schaber disclosed she is a member of the Alaska Pharmacists Association (AKPhA) Legislative Committee.

Agenda Item #3 Consent Agenda Items

Brief Discussion:

- Review/Approve Meeting Agenda
- Review/Approve Previous Meeting Minutes
- Review Lost or Stolen Controlled Substances/DEA 106s
- Review Well Being Index
- Applicability of USP reference in Food, Drug & Cosmetic Act Email

Motion: James Henderson moved to approve the consent agenda items which included the November 16, 2023, meeting agenda as written, December 07, 2023, meeting minutes as written, lost or stolen controlled substances/DEA 106s, and well-being index, and Applicability of USP reference in Food, Drug & Cosmetic Act Email. Seconded by Carla Hebert.

Recorded Votes:

Ashley Schaber - Yes
 Sara Rasmussen - Absent
 James Henderson - Yes
 Carla Hebert - Yes
 Ramsey Bell – Yes
 Sylvain Novion – Yes

It was resolved to approve the consent agenda items as written.

Agenda Item #4 Investigations Review

Discussion:

- Handley, Investigator and Billy Homestead, Senior Investigator
 - Investigative Report from November 03, 2023, through February 05, 2024
 - Open Cases: 60
 - Closed Cases: 26
 - License Actions: 11
 - Conducted reviews of open cases

Motion: On a motion made by Ashley Schaber in accordance with AS 44.62.310(c)(2) and seconded by Sara Rasmussen, the board moved to enter executive session for the purpose of discussing subjects that tend to prejudice the reputation and character of any person, provided the person may request a public discussion. No request was made for public discussion. Ashley Schaber, Sara Rasmussen, Sylvain Novion, Carla Hebert, Michael Bowles, Lisa Sherrell, Billy Homestead, and Holly Handley were authorized to remain in the room. Case discussed will be 2023-001178.

Recorded Votes:

Ashley Schaber - Yes
 Sara Rasmussen - Yes
 James Henderson - Yes
 Carla Hebert - Yes
 Ramsey Bell – Yes
 Sylvain Novion – Yes

It was resolved to enter executive session in accordance with AS 44.62.310(c)(2).

Off record for executive session at 9:12am

On record from executive session at 9:48am

No motions were made during the executive session.

Motion: Sara Rasmussen motioned to approve the application denial order for case 2023-001178 as written. Seconded by Ashley Schaber.

Recorded Votes:

Ashley Schaber - No
Sara Rasmussen - No
James Henderson - No
Carla Hebert - No
Ramsey Bell – No
Sylvain Novion – No

It was not resolved to the application denial order for case 2023-001178 as written, the motion fails.

Motion: Sara Rasmussen motioned to approve the license application for case 2023-001178 as written. Seconded by Ashley Schaber.

Recorded Votes:

Ashley Schaber - Yes
Sara Rasmussen - Yes
James Henderson - Yes
Carla Hebert - Yes
Ramsey Bell – Yes
Sylvain Novion – Yes

It was resolved to approve the license application for case 2023-001178 as written.

Motion: Ashley Schaber moved to accept the board orders for cases 2022-000434, 2023-000194, 2023-000365, 2023- 000746, 2023-000753, 2023-000824, 2023-000911, 2023-000942, 2023-000972, 2023-001009, 2023-001011, and 2023-001012 as written. Seconded by Sara Rasmussen.

Recorded Votes:

Ashley Schaber - Yes
Sara Rasmussen - Yes
James Henderson - Yes
Carla Hebert - Yes
Ramsey Bell – Yes
Sylvain Novion – Yes

It was resolved to accept the to accept the board orders for cases 2022-000434, 2023-000194, 2023-000365, 2023- 000746, 2023-000753, 2023-000824, 2023-000911, 2023-000942, 2023-000972, 2023-001009, 2023-001011, and 2023-001012 as written.

- Task created for all board members to review and provide input on the professional fitness questions to address at the next meeting.

Agenda Item #5 Board Business**Discussion:**

- Application reviewed, Confidential - Executive Session.
- The board reviewed the 2024 Strategic Plan.
- The board discussed non-punitive addiction treatment assistance for licensees that self-refer.
 - Michael Bowles addressed the board on the discussions the three medical boards (Pharmacy, Nursing, Medical) have had to move this process forward.
 - Carla Hebert stated she would like to see this move forward, the rest of the board agreed.
 - The board would like to approve regulation addressing non-punitive addiction treatment.
- The board discussed the way forward on the Just Culture initiative.
 - Sara Chambers, Boards and Regulations Advisor for the Department of Commerce, Community, and Economic Development, addressed the board on the division's way forward.
 - Carla Hebert asked if the other medical boards have started discussions on Just Culture.
 - Carla Hebert asked if continuous quality improvement could be incorporated into inspections.
 - Sara Chambers discussed reviewing the disciplinary matrix and considering the Just Culture model while considering discipline decisions.
 - Ashley Schaber stated she would like to see a Just Culture summit with all of the boards.
 - Sara Chambers stated it may be difficult to coordinate all members of the boards, but representatives would probably work.
 - James Henderson stated he is not sure how this works for the board.
 - Sara Chambers discussed the Controlled Substances Advisory Committee (CSAC) and gave the board an update on where the CSAC is and that the position is vacant for the person that manages the CSAC.
 - Sara Rasmussen asked if there is a statutory requirement for a number of meetings annually.
 - Sara Chambers confirmed there is a statutory requirement.
 - Ashley Schaber stated she wants to keep this as a priority for the board. There are concerns with opioid shortages in Alaska and this needs to remain a priority.
 - Sara Rasmussen stated it may be beneficial to look at a statute change moving the responsibility of CSAC over to board of pharmacy.
 - Ashley Schaber agreed with Sara Rasmussen. The board has been trying to schedule a CSAC meeting for over a year. It's important to have the CSAC meet.
 - Ashley Schaber stated a statute change to move CSAC responsibility to the board of pharmacy would be beneficial.
 - Sara Chambers stated the board can certainly make the recommendation however this is on the criminal division in the department of law due to the responsibility to classify controlled substances. Sara Chambers stated it may be late in legislative session to get this in at this time. Sara Chambers stated it may be better staffed in a different agency.
- The board discussed updating the disciplinary matrix.
 - The board discussed delegating authority to the Executive Administrator for disciplinary decisions of late forms based on disciplinary matrix guidelines.
 - The board discussed changes that need to be made to the disciplinary matrix based on regulations changes over the past year.
- The board discussed a letter of concern from medical providers about opioid prescribing in Alaska.

- Linda Smith, MD, Hospice and Palliative care Specialist with Alaska Women's Cancer Care, introduced herself to the board.
- Ursula McVeigh, MD, Medical Director with Providence Alaska Medical Group, introduced herself to the board.
 - Medical providers in Alaska have experienced quite a few issues obtaining medications for pain management strategies.
 - Pharmacies in Anchorage are running out of stock; having to do “short fills”.
 - Providers are seeing inadequate supplies in Anchorage and the Mat-Su Valley.
 - There seems to be an issue of supply and demand that pharmacies are not able to explain to providers.
 - Short fills/inadequate fills lead to multiple prescription writing to try and complete a prescription.
 - Patients are having to go the emergency room (ER) in pain crisis due to not being able to get their full prescription.
 - It has been like this for at least a year.
- Carla Hebert stated problems with ordering medications and manufacturer shortages. Tries to order fentanyl and hydrocodone and the deliveries do not have the full order. The manufacturer is not telling the wholesaler. Medications get bumped from orders. The airplane problems are effecting getting medications into the state.
- Ramsey Bell stated she is experiencing wholesalers having very little in stock. Pharmacies are not sure what wholesalers have as far as medications, so they are unsure where to tell patients to go to get their prescriptions filled. The DEA is limiting production is the explanation from the wholesaler.
- James Henderson stated he agrees, the DEA is limiting wholesalers due to the opioid misuse epidemic.
- Carla Hebert stated the wholesaler can limit pharmacies as well, without notice.
- Sylvain Nouvion stated, even after filling out the paperwork they still may not fill the order even with adequate information provided.
- Ashley Schaber stated she received an email about the DEAs annual supply chain conference and is hoping at least one member attends the conference and reports back to the board with takeaways from the conference.
- Ursula McVeigh stated discussions need to address the need for opioids when addressing the opioid misuse epidemic. Nobody should have to go to the ER for their medications.
- Linda Smith stated it is helpful to understand this is a supply chain issue. The demographic in Alaska is changing and the aging population is growing exponentially. Hopefully the CSAC can address this.
- Sara Rasmussen stated a letter of resolution from all medical boards to the DEA addressing the shortages may be an effective approach.
- The board discussed committee assignments.
 - Ashley Schaber stated the most active committee has been that statute and regulation committee.
 - Carla Hebert asked what is happening with the Multistate Pharmacy Jurisprudence Examination (MPJE).
 - Ashley Schaber stated there is a regulation project currently with the department of law to remove the requirement of pharmacist applicants taking and passing the MPJE.
- 2024 Conferences – The board decided on conference attendees.

- April 01-04, 2024 – RX and Illicit Drug Summit (Atlanta, GA)
 - Sylvain Nouvion is attending this conference.
- April 30 – May 02, 2024 - DEA's 2nd Annual Supply Chain Conference (Virtual)
 - James Henderson
- May 14-17, 2024 – NABP Annual Meeting (Fort Worth, TX)
 - Sara Rasmussen
 - TBD, possibly Sylvain Nouvion
- September 13-14, 2024 – AKPhA Fall Health System Academy Conference (Girdwood, AK)
 - TBD, board member attendee
- October 20-23, 2024 – NABP District 6, 7, 8 Meeting (Albuquerque, NM)
 - Carla Hebert
- The board discussed H.R 1770 - Equitable Community Access to Pharmacist Services Act.
- Task created for the board to review the inspection sheet to incorporate continuous quality improvement.
- Task created for the board to put Just Culture on the April agenda and continue the conversation with other boards.
- Task created for Michael Bowles to bring the Executive Administrators for the medical board and board of nursing into the conversation with Linda Smith and Ursula McVeigh.
- Task created for the board to request the nursing and medical board chairs to collaborate on a letter of resolution to the DEA.
- Task for a member of the board to write a FAQ addressing palliative care and opioid shortages.
- Sara Chambers stated she will continue to work with Department of Law regarding CSAC logistics and scheduling.

Motion: Ashley Schaber moved to initiate a regulations project to add language to 12 AAC 52.940 by approving the following language for public comment, unless substantive changes are made by the regulations specialist or Department of Law:

“The board may offer a licensee subject to this section the opportunity to participate in an alternative to probation program. Whether a licensee may participate in an alternative to probation program is at the discretion of the board. A licensee participating in an alternative to probation program shall meet the terms of the probation required by the board under the alternative to probation program. The board will keep a licensee’s participation in an alternative to probation program confidential, except as required by law.”

Seconded by Sara Rasmussen.

Recorded Votes:

Ashley Schaber - Yes

Sara Rasmussen - Yes

James Henderson - Yes

Carla Hebert - Yes

Ramsey Bell – Yes

Sylvain Nouvion – Yes

It was resolved to initiate a regulations project to add the aforementioned language to 12 AAC 52.940.

Motion: Sara Rasmussen moved to have the Alaska Board of Pharmacy submit a statement of support to HR 1770 The Equitable Community Access to Pharmacist Services Act. Seconded Carla Hebert.

Recorded Votes:

Ashley Schaber - Yes
Sara Rasmussen - Yes
James Henderson - Yes
Carla Hebert - Yes
Ramsey Bell – Yes
Sylvain Nouvion – Yes

It was resolved to have the Alaska Board of Pharmacy submit a statement of support to HR 1770 The Equitable Community Access to Pharmacist Services Act.

Motion: Ashley Schaber moved to allow the Executive Administrator to update the disciplinary matrix violation types and regulation reference columns to align with all future statute and regulation changes. Seconded by Carla Hebert:

Recorded Votes:

Ashley Schaber - Yes
Sara Rasmussen - Absent
James Henderson - Yes
Carla Hebert - Yes
Ramsey Bell – Yes
Sylvain Nouvion – Yes

It was resolved to allow the Executive Administrator to update the disciplinary matrix violation types and regulation reference columns to align with all future statute and regulation changes.

Motion: Ashley Schaber moved to delegate authority to the Executive Administrator to make disciplinary decisions of late forms based in the violations recommendation section of the disciplinary matrix after review by Investigations. Seconded by Sylvain Nouvion:

Recorded Votes:

Ashley Schaber - Yes
Sara Rasmussen - Yes
James Henderson - Yes
Carla Hebert - Yes
Ramsey Bell – Yes
Sylvain Nouvion – Yes

It was resolved to delegate authority to the Executive Administrator to make disciplinary decisions of late forms based in the violations recommendation section of the disciplinary matrix after review by Investigations.

Agenda Item #6 Public Comment Period

Discussion: No public comments made.

Agenda Item #7 Industry Updates

Discussion:

- Alaska Pharmacists Association (AKPhA) – Brittany Keener, PharmD, MPH, BCPS and Brandy Seignemartin, PharmD, AKPhA Executive Director provided an update on the following items:
 - Thanked the board of pharmacy for the work they are doing addressing all pertinent issues including the issues addressing opioid shortages in Alaska.
 - Advocating SB 121
- Alaska Department of Health – John Boston, DO, CMD, provided an update on the following items:
 - Staffed to assist with the Geneva Woods closure.
 - Geneva Woods stated they will not close medi-set portion until October 01, 2024.
 - Addressed 75% rule which states that a pharmacy must fill 75% or more of their prescriptions to get a higher dispensing fee; thought it would be an easy fix. The software does not have the ability to pay a different dispensing fee. The software is provider specific, not service specific.
 - The department of health Commissioner's office would like to have regulations change in place by October 01, 2024, addressing the 75% rule.
 - Looking at a medi-set fee vs dispensing fee.

Agenda Item #8 Adjourn for Lunch (off record at 12:29pm)

Ashley Schaber made a motion to adjourn for lunch. Seconded by James Henderson.

Roll Call:

Unanimous consent.

It was resolved to adjourn for lunch.

Agenda Item #9 Roll Call/Call to Order (on record at 1:01pm)

Roll Call:

Ashley Schaber - Present
 Sara Rasmussen - Present
 James Henderson - Present
 Carla Hebert - Present
 Ramsey Bell – Present
 Sylvain Nouvion – Present

Sara Rasmussen left the meeting at 1:15pm.

Sara Rasmussen joined the meeting at 2:15pm

Agenda Item #10 Division Updates

Discussion:

- Pacifico National DBA AmEx Pharmacy Hearing and Recommendation Review
- Michael Bowles, Executive Administrator
 - Informed the board of the new Occupational Licensing Examiner, Brigham Perez.

- Provided the board with an update of the timeline for going live with online applications.
- Provided the board with application processing statistics.
- Task created for Michael Bowles to find how many Pharmacy Technicians are in state vs out of state.
- Lisa Sherrell, Prescription Drug Monitoring Program (PDMP) Manager
 - Provided PDMP updates.
 - The board discussed changes in dispensing statuses and zero reporting requirements.

Motion: Ashley Schaber motioned to move the board into deliberative session under AS 44.62.310(d) solely to make a decision in the following adjudicatory proceeding:

In the matter of Pacifco National, Inc. dba AmEx Pharmacy, Board Case Number 2023-000289, Office of Administrative Hearings Case Number 23-0263-PHA.

The parties, their attorneys, all members of the Board's staff, and all members of the public will be excluded from the deliberative session. The administrative law judge will be invited to remain with the board during the deliberative session. Seconded by James Henderson.

Recorded Votes:

Ashley Schaber - Yes

Sara Rasmussen - Yes

James Henderson - Yes

Carla Hebert - Yes

Ramsey Bell – Yes

Sylvain Novvion – Yes

It was resolved to move the board into deliberative session under AS 44.62.310(d) solely to make a decision in the following adjudicatory proceeding:

In the matter of Pacifco National, Inc. dba AmEx Pharmacy, Board Case Number 2023-000289, Office of Administrative Hearings Case Number 23-0263-PHA.

The parties, their attorneys, all members of the Board's staff, and all members of the public will be excluded from the deliberative session. The administrative law judge will be invited to remain with the board during the deliberative session.

Off record for executive session at 1:05pm

On record from executive session at 1:12pm

No motions were made during the deliberative session.

Motion: Ashley Schaber motioned pursuant to AS 44.64.060(e)(1), to move that the Board adopt the final decision after remand for Board Case Number 2023-000289, Office of Administrative Hearings Case Number 23-0263-PHA as its final decision in this matter. Seconded by Sara Rasmussen.

Recorded Votes:

Ashley Schaber - Yes
Sara Rasmussen - Yes
James Henderson - Yes
Carla Hebert - Yes
Ramsey Bell – Yes
Sylvain Nouvion – Yes

It was resolved pursuant to AS 44.64.060(e)(1), to move that the Board adopt the final decision after remand for Board Case Number 2023-000289, Office of Administrative Hearings Case Number 23-0263-PHA as its final decision in this matter.

Agenda Item #11 Public Comment Period

Discussion: No public comments were made.

Off record at 2:20pm for break.

On record at 2:27pm.

Recorded Votes:

Ashley Schaber - Yes
Sara Rasmussen - Yes
James Henderson - Yes
Carla Hebert - Yes
Ramsey Bell – Yes
Sylvain Nouvion – Yes

Quorum was made.

Agenda Item #12 Statutes and Regulations

Discussion:

- The board discussed the Implementing Solutions Report.
 - The board went section by section to discuss where the board has moved on the listed actions.
 - Ashley Schaber discussed a newsletter coming from the board to inform licensees of goings on.
 - James Henderson stated the board needs to have the conversation concerning professional fitness questions to ensure competent people are practicing.
 - The board discussed whether there should be certain types of continuing education classes required.
- The board discussed whether a statute change addressing score transfers is needed.
 - There is a 9-month gap in statute creating a barrier for applicants.
 - Ashley Schaber recommended the removal of AS 08.80.145(4) due to the gap created by score transfer.
- The board discussed clarifying 12 AAC 52.020(f)
 - Defining “Ownership” (at which level).
- The board discussed clarifying 12 AAC 52.235(a)(1)(C)

- The pharmacy uses software that displays the image or graphical description of the correct drug being verified; however, if there is any deviation between the image or graphical description and the actual product being distributed, a pharmacist must review and dispense the order.
- Consider hospital technicians involved in this process. Currently language appears to limit process to just technicians working in the ambulatory dispensing setting.
- The board discussed clarifying 12 AAC 52.855(b)
 - Only pharmacists dispensing controlled substances should register with the PDMP.
 - Michael Bowles and Lisa Sherrell discussed how the language is causing confusion to applicants.
- The board discussed bringing into alignment 12 AAC 52.698 - FDA Good Manufacturing Practices
 - Language under manufacturer regulations should be the same as outsourcing facilities, “submits the results of the most recent Good Manufacturing Practice (GMP) inspection by the United States Food and Drug Administration.”
- The board discussed 12 AAC 52.540
 - DEA 106 requirement clarification, does the board need to review these?
 - James Henderson stated DEA 106s should go to the investigative team for review.
 - Carla Hebert stated, if there are trends the DEA will investigate.
- The board discussed aligning statutes and regulations with pharmacist intern vs pharmacy intern language.
 - “Pharmacy Intern” is used 5 times in statute and 11 times in regulation. “Pharmacist Intern” is used 0 times in statute and 47 times in regulation.
- The board discussed incorporation of United States Pharmacopeia (USP) 797 and 800 Into Regulation
 - Following USP guidelines should fall under the standard of care model.
- The board discussed collaborative practice agreements.
 - Should board approval be a requirement or can these be kept at the physician/pharmacist level?
 - Pharmacists should submit protocols to the board to maintain in their licensing record, but the board does not need to approve the protocol under standard of practice model.

Task created to have Michael Bowles schedule the board with the statute and regulations meeting and a meeting with investigations staff concerning recusal during investigative matters.

Task created to have Michael Bowles follow up with Idaho and Senior Investigator Homestead on DEA 106s.

Task created to have Michael Bowles see if a regulation cleanup can happen for pharmacy intern language throughout regulations.

Motion: James Henderson moved to remove section (4) from AS 08.80.145. Seconded by Sylvain Nouvion:

Recorded Votes:

Ashley Schaber - Yes

Sara Rasmussen - Yes

James Henderson - Yes

Carla Hebert - Yes
 Ramsey Bell – Yes
 Sylvain Nouvion – Yes

It was resolved to remove section (4) from AS 08.80.145.

Motion: Ashley Schaber moved to initiate a regulations project to add language to 12 AAC 52.995 by approving the following language for public comment, unless substantive changes are made by the regulations specialist or Department of Law:

“owner” means a person or entity who is the legal operator of a licensed pharmacy or facility and is assigned a unique federal employer identification number (EIN) for the transaction of business.

“change of ownership”

(a) means a change in the federal employer identification number (EIN) with the parent level or any transfer of a beneficial interest in a business entity licensed or registered by the board to any person or entity, in which the transfer results in the transferee’s holding 50% or more of the beneficial interest in that license or registration. A change of ownership includes

(1) For an individual, a person who

(A) sells a pharmacy or facility;

(B) enters into a partnership with others; or

(C) becomes incorporated.

(2) For partnership,

(A) sells a pharmacy or facility;

(B) membership changes and dissolves; or

(C) becomes incorporated

(3) For a corporation,

(A) sells or disposes all assets;

(B) changes from a limited liability corporation to a corporation; or

(C) merges into or consolidates with another corporation.

(b) The following activities do not constitute a change of ownership:

(1) an individual incorporates themselves and there are no other shareholders;

(2) 20% or less of a stock change occurs; or

(3) change in managing officers that does not also result in subsection (a) of this section.

Seconded by Carla Hebert.

Recorded Votes:

Ashley Schaber - Yes
 Sara Rasmussen - Yes
 James Henderson - Yes
 Carla Hebert - Yes
 Ramsey Bell – Yes
 Sylvain Nouvion – Yes

It was resolved to initiate a regulations project adding the aforementioned language to 12 AAC 52.995.

Motion: James Henderson moved to initiate a regulations project to add and remove language to 12 AAC 52.235(a)(1)(C) by approving the following language for public comment, unless substantive changes are made by the regulations specialist or Department of Law:

“The pharmacy uses software that displays the image or graphical description of the correct drug being verified **or the institutional facility uses software that performs and verifies a barcode scan prior to administration; and**” as well as remove the language “[However, if there is any deviation between the image or graphical description and the actual product being distributed, a pharmacist must review and dispense the order; and].”

Seconded by Carla Hebert.

Recorded Votes:

Ashley Schaber - Yes
Sara Rasmussen - Yes
James Henderson - Yes
Carla Hebert - Yes
Ramsey Bell – Yes
Sylvain Novvion – Yes

It was resolved to initiate a regulations project adding and removing the aforementioned language to 12 AAC 52.235(a)(1)(C).

Motion: James Henderson moved to initiate a regulations project to amend the language in 12 AAC 52.855(b) by approving the following language for public comment, unless substantive changes are made by the regulations specialist or Department of Law:

“A licensed pharmacist dispensing a schedule II, III, or IV controlled substance in this state shall register with the PDMP within 30 days of initial dispensing.”

Seconded by Ashley Schaber

Recorded Votes:

Ashley Schaber - Yes
Sara Rasmussen - Yes
James Henderson - Yes
Carla Hebert - Yes
Ramsey Bell – Yes
Sylvain Novvion – Yes

It was resolved to initiate a regulations project to amend 12 AAC 52.855(b) with the aforementioned language.

Motion: Ashley Schaber moved to initiate a regulations project to add language to 12 AAC 52.698 by approving the following language for public comment, unless substantive changes are made by the regulations specialist or Department of Law:

“submits the results of the most recent Good Manufacturing Practice (GMP) inspection by the United States Food and Drug Administration.”

Seconded by Carla Hebert.

Recorded Votes:

Ashley Schaber - Yes

Sara Rasmussen - Yes

James Henderson - Yes

Carla Hebert - Yes

Ramsey Bell – Yes

Sylvain Nouvion – Yes

It was resolved to initiate a regulations project adding the aforementioned language to 12 AAC 52.698.

Sara Rasmussen and Ramsey Bell left the meeting at 4:37pm.

Motion: Ashley Schaber moved to initiate a regulations project to amend language to 12 AAC 52.240(a) by approving the following language for public comment, unless substantive changes are made by the regulations specialist or Department of Law:

“A pharmacist planning to exercise collaborative practice authority in the pharmacist’s practice by initiating or modifying drug therapy in accordance with a written protocol established and approved for the pharmacist’s practice by a practitioner authorized to prescribe drugs under AS 08 must submit the completed written protocol to the board” [and be approved by the board before implementation].

Seconded by Sylvain Nouvion.

Recorded Votes:

Ashley Schaber - Yes

Sara Rasmussen -

James Henderson - Yes

Carla Hebert - Yes

Ramsey Bell –

Sylvain Nouvion – Yes

It was resolved to initiate a regulations project amending 12 AAC 52.240(a) with the aforementioned language.

Motion: Ashley Schaber moved to initiate a regulations project to amend language to 12 AAC 52.430 by approving the following language for public comment, unless substantive changes are made by the regulations specialist or Department of Law:

“A pharmacy or pharmacist that prepares or dispenses sterile pharmaceuticals shall adhere **to the current standard of care.** [guidelines established by the board in the pamphlet titled, “Sterile Pharmaceuticals,” dated February 2008, and incorporated by reference in this section.]”

Seconded by James Henderson.

Recorded Votes:

Ashley Schaber - Yes

Sara Rasmussen -

James Henderson - Yes

Carla Hebert - Yes

Ramsey Bell –

Sylvain Nouvion – Yes

It was resolved to initiate a regulations project amending 12 AAC 52.430 with the aforementioned language.

Agenda Item #13 Chair Final Comments

Discussion:

- Next meeting is April 11, 2024
- A special meeting will be scheduled when the current regulations project currently with the department of law comes out of public comment.

Agenda Item #14 Adjourn

Motion: Carla Hebert motioned to adjourn. Seconded by Ashley Schaber.

Recorded Votes:

Unanimous consent.

It was resolved to adjourn at 5:05pm.